ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1665

Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease

Remy Pollock1, Laila Zaman1, Vinod Chandran2 and Dafna D Gladman3, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, Epigenetics, Gene Expression, psoriasis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Heritable epigenetic phenomena may play a role in the parent-of-origin effect observed in psoriasis and psoriatic arthritis (PsA). A previous epigenome-wide association study (EWAS) identified differentially methylated regions (DMRs) in sperm cells of PsA and psoriasis patients without PsA (PsC) compared to controls. This study aimed to assess differential methylation and expression of these regions in somatic tissues.

Methods: Genomic DNA was extracted from whole blood of PsC patients (n=24), PsA patients satisfying the CASPAR criteria (n=13), and controls (n=19). All subjects were males whose semen was previously analyzed by EWAS. DNA was bisulfite converted and the most biologically interesting and statistically significant EWAS hits (oxysterol binding protein like 5 [OSBPL5], myelin basic protein [MBP], imprinted maternally expressed transcript H19, small nucleolar RNA C/D box 115 [SNORD115], E74 like ETS transcription factor 5 [ELF5], interleukin 22 [IL22], protein tyrosine phosphatase receptor type N [PTPRN2], junctional adhesion molecule 3 [JAM3], and cysteinyl-tRNA synthetase 2 [CARS2]) were analyzed by pyrosequencing. Group-wise methylation differences were compared by Student’s t test or Wilcoxon rank sum test. Multivariable logistic regression was also performed to adjust for age and psoriasis area and severity index (PASI). Whole blood RNA was collected in Tempus and Paxgene tubes and extracted with their respective kits. Differential expression was analyzed by qRT-PCR using the ΔΔCt method with normalization to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Results:  In whole blood, CpG sites within JAM3, MBP, and PTPRN2 were differentially methylated in PsA vs. controls. JAM3 and ELF5 were differentially methylated in PsA vs. PsC. MBP was differentially methylated in PsC vs. controls (p<0.05). After adjustment for age, MBP (OR=0.1, 95% CI 0.1-0.75, p=0.03) and PTPRN2 (two CpG sites: OR=2.1, 95% CI 1.0-4.3, p=0.04 and OR=2.2, 95% CI 1.0-4.9, p=0.049) remained significantly associated with PsA vs. controls. After adjustment for age and PASI, JAM3 (OR=26.7, 95% CI 2.6-276, p=0.006) and ELF5 (OR=31.5, 95% CI 1.6-628, p=0.02) remained significantly associated with PsA vs PsC. No CpG sites were differentially methylated in PsC vs. controls in age-adjusted analyses. All genes except for ELF5, PTPRN2, and IL22 were expressed at detectable levels in whole blood. Preliminary qRT-PCR results showed significantly higher expression of CARS2 mRNA transcripts in PsA (fold change=1.18, p=0.02) and PsC patients (fold change=1.24, p=0.046) compared to controls, but no significant differences in the levels of JAM3 and MBP between groups.

Conclusion:  Several germ line DMRs associated with PsC and PsA were differentially methylated in whole blood. The presence of these DMRs in both the germ line and whole blood suggests they may be heritable epigenetic phenomena associated with PsC and PsA. Investigation of these sites in additional somatic tissues, and in extended patient populations is necessary to strengthen the evidence that they are true heritable epigenetic variations.


Disclosure: R. Pollock, None; L. Zaman, None; V. Chandran, None; D. D. Gladman, AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 2,AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 5.

To cite this abstract in AMA style:

Pollock R, Zaman L, Chandran V, Gladman DD. Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/validation-of-germ-line-epigenetic-variants-associated-with-psoriatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-germ-line-epigenetic-variants-associated-with-psoriatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology